Browse by Journal Title

Article

Treatment of young patients with HNF1A mutations (HNF1A-MODY).
Raile, K., Schober, E., Konrad, K., Thon, A., Grulich-Henn, J., Meissner, T., Woelfle, J., Scheuing, N. and Holl, R.W.
Diabetic Medicine 32 (4): 526-530. April 2015

Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone.
Luedtke, A., Heck, K., Genschel, J., Mehnert, H., Spuler, S., Worman, H.J. and Schmidt, H.H.
Diabetic Medicine 22 (11): 1611-1613. November 2005

Postprandial glucose and vascular disease.
Haller, H.
Diabetic Medicine 14 : S50-S56. 1 January 1997

Phenotyping and genotyping patients with cardiovascular risk factors.
Schuster, H.
Diabetic Medicine 14 : S57-S59. 1 January 1997

Mechanisms of hepatic chylomicron remnant clearance.
Willnow, T.E.
Diabetic Medicine 14 : S75-S80. 1 January 1997

Letter

Serum levels of L-arginine analogues and glutathione peroxidase and catalase gene variants in Type 2 diabetes mellitus patients.
Szelestei, T., Bähring, S., Wagner, Z., Aydin, A., Molnar, G.A., Kocsis, B., Nagy, J. and Wittmann, I.
Diabetic Medicine 22 (3): 356-357. 1 January 2005

Editorial

The postprandial state: how glucose and lipids may affect atherosclerosis and cardiovascular disease: introduction.
Haller, H.
Diabetic Medicine 14 : S5. 1 January 1997